| Price | $3.66 |
| Year Range | $3.58 – $20.8 |
| Market Cap | $6.9M |
| Industry | Biotechnology |
What Is NeuroSense Therapeutics’s AI Stock Analysis?
NeuroSense Therapeutics’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks NeuroSense Therapeutics’s momentum in near-real time.
NeuroSense Therapeutics (NRSN) has an AltIndex AI Score of 48/100, currently a Hold signal. The AI Score distills NeuroSense Therapeutics's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
NeuroSense Therapeutics’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of NeuroSense Therapeutics — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving NRSN’s AI Score?
Technicals
Today's stock price is $3.66. This represents a decrease of 47.26% compared to a month ago, which may be concerning in the short-term. However, compared to a year ago, there is a decrease of 84.62%, which could be a cause for long-term concern. The trend is bearish. The current SMA10 is $3.87, which is lower than the previous SMA10 of $3.95. This suggests a potential downward trend in price movement. The RSI is 48.1, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
The business outlook among employees at NeuroSense Therapeutics is neutral. NeuroSense Therapeutics has an estimate of 3,000 visitors to their webpage. The number of visitors is down by -50% in the last couple of months, a worrisome trend as this can indicate a loss in customers.
Explore NeuroSense Therapeutics’s job postings, web traffic and app downloads.
Sentiment & social
Add to that that the sentiment is down by -79% in the last couple of weeks, an even more concerning trend. NeuroSense Therapeutics has 1,600 followers on their Instagram page. The number of followers is up by 6% in the last couple of months, indicating an increased interest in the company.
Track NeuroSense Therapeutics’s market sentiment.
Frequently Asked Questions: NeuroSense Therapeutics AI Stock Analysis
NeuroSense Therapeutics's AltIndex AI Score is 48/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates NeuroSense Therapeutics a Hold (48/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of NeuroSense Therapeutics — company overview, fundamentals, technicals and alternative data, with a recommendation. See the NRSN AI Score or sign up to read the full thesis.
